|
Therapeutic approaches | Cancer | Drugs | Ref. |
|
Killing TAMs or inhibiting TAM recruitment and differentiation | | | |
Blocking the murine or human IL-4 receptor α (IL4Rα or CD124) | — | RNA aptamer | [125] |
Inducing apoptosis in TAMs via Kv1.3 and Kv1.5 potassium channels | — | Membrane-permeant drugs | [118] |
Selectively cytotoxic for TAMs and their circulating precursors (monocytes) by activating caspase 8-dependent apoptosis | Sarcoma and ovarian carcinoma | Trabectedin | [126] |
Reducing macrophage motility, inhibiting macrophage infiltration of irradiated tumors | Colon carcinoma | Dequalinium-14 | [12] |
Suppressing of tumor-associated macrophage differentiation | Gallbladder cancer | Interferon-γ | [120] |
Regulation of TAM polarization | | | |
Reversing TAM orientation and polarization from M2- to M1-type TAMs | Breast cancer | Dimethyl sulfoxide | [124] |
Reeducating CD163+ TAMs to M1 macrophages through TLR4-mediated pathway | MPE | PA-MSHA | [23] |
Shifting the M1/M2 TAMs balance by M-CSFR signaling blockade | Lung carcinoma and breast carcinoma | Anti-M-CSFR antibody | [125] |
Modulating the M2/M1 macrophage ratio | Lung cancer | IFNγ and/or celecoxib | [126] |
Blocking factors and pathways associated with protumor function of TAMs | | | |
Inhibiting the paracrine loop between TAM and PCa cells via NF-κB regulation | Prostate cancer | Somatostatin derivate (smsDX) | [128] |
Suppressing chemokine (C-C motif) ligand 2 expression in tumor-associated macrophage | Lung carcinoma | Luteolin | [129] |
Inhibiting macrophage-induced EMT by downregulation of EGFR pathway | Non-small cell lung cancer | Cannabinoid receptor-2 agonist | [69] |
|